TeamDrive
RUS

RMI Partners

www.rmivc.com

RMI Patners - a pharmaceutical project management company with a focus on investments to out of the box developments in medical, pharmaceutical and biotechnology sectors worldwide.

The company’s key mission – to develop and introduce innovative drugs and medical equipment into the market and to create world-class Russian domiciled expertise in Life Sciences venture financing.

Leonid Melamed"It is strategically important that Russian developers of innovative pharmaceuticals appear large in number. Three or thirty companies of this kind in place will not resolve the problem. In the Silicon valley - there are tens of thousands of them, therefore the probability of success is rather high. Drug development industry is alive only if millions of people are dealing with it consolidated in tens of thousands of companies. To make this happen at our place, people with good ideas should be aware of how to become an accurate applicant, and also there must be institutions willing to invest and perform a function of business angels".

Media Center

  • 22 September 2017

    SPIC’s will ensure more predictability for pharmaceutical companies in Russia

    A meeting of the working group of the Coordination Council in the Area of Circulation of Medicines and Medical Devices held in the Russian Union of Industrialists and Entrepreneurs (RSPP) examined the state and development prospects of manufacturing the drugs for the treatment of oncological diseases in Russia.

  • 22 September 2017

    Cancer biobank Indivumed and CRO Helomics team up on precision medicine

    Indivumed, which has a large cancer biobank, has partnered with cancer research specialist Helomics to analyze human cancer biospecimens and relevant clinical datIndivumed, which has a large cancer biobank, has partnered with cancer research specialist Helomics to analyze human cancer biospecimens and relevant clinical data collected from patients around the world to help advance research in personalized cancer treatments. collected from patients around the world to help advance research in personalized cancer treatments.

  • 21 September 2017

    In a world of change, big pharma remains a constant

    Analysts casting their eyes forward to 2022 see big pharma maintaining its position in the sector, protected by vast war chests and ready to pounce on any newcomer that shows promise. Here pharmaphorum’s Andrew McConaghie crunches the numbers.

  • 20 September 2017

    India’s Zydus Cadila inks deal to produce varicella vaccine in Russia

    India’s Zydus Cadila inks deal to produce varicella vaccine in Russia

    Zydus Cadila, an Indian injectables maker, said it reached a deal with Russia’s Pharm Aid to manufacture its varicella vaccine for the Russian Federation. The Russians have been pressuring foreign pharmaceutical companies to engage in local production if they want to be in its market. Earlier this year, Russia-based NovaMedica announced it began work on a new plant in Russia’s Kaluga region where it will produce 30 of Pfizer’s sterile injected generic medications for the local market.

Read more